Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
Subjects achieving a clinical response in study OX4218s with a biomarker reduction or symptom
response are eligible to enroll in this rollover study to continue once every three weeks
fosbretabulin infusions for up to one year.